Shai Yarkoni

Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target disease progression by directly influencing the tissue regeneration process. Central to Collgard's novel approach is its lead drug candidate, Tempostatin (Halofuginone hydrobromide). Tempostatin is a multi-indication, small-molecule drug candidate that has been identified by the company as influencing a 'master switch' in the body's tissue repair process. As a potent and selective regulator of stromal cell activation, cell migration and excessive collagen type I synthesis, Tempostatin makes it possible to harness and direct the tissue repair process for treating diseases acting at the tissue level. Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs. These solutions are based on highly specific control of the tissue repair process. Current programs target the following indications vascular restenosis, end-organ fibrosis, selected cancers and dermal fibroproliferative disorders. Tempostatin holds exceptional promise based on addressing a fundamental underlying pathological process that is not accessible to other current therapeutic approaches. In developing Tempostatin, Collgard seeks to offer novel therapeutic solutions as well as extend the effectiveness of existing therapies. Founded in 1996, Collgard Biopharmaceuticals is a privately held, clinical stage company, led by a global team of medical and drug development experts based in Atlanta and Tel Aviv. Scientific and clinical collaborators include The Mayo Clinic, the U.S. NCI, the EORTC, and Harvard Medical School. Collgard was founded by Medica Venture Partners. Additional investors include Mayo Medical Ventures, Denali Ventures, Yozma Group, and Comsor.

Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.

SN'E Rosetta IP Technology Transfer Co. Ltd. engages in the provision of intellectual property commercialization services. Its services include transfer guidelines, intellectual property branding, marketing, and business development services. The company was founded by Omri Raisman, Amos Konforti, Shai Yarkoni, and Nahum Gerardo in 2014 and is headquartered in Caesarea, Israel.

Treebute.io Ltd. operates as a business intelligence platform. The firm serves in the area of artificial intelligence, business intelligence, information technology and innovation management. The company was founded by Naveh D. Shetrit, Omer Gazit and Shai Yarkoni and is headquartered in Tel Aviv, Israel.

Part of EnCellX, Inc., Cellect Biotherapeutics Ltd. is an Israeli biotechnology company that develops cellular therapeutics. The company is based in Kfar Saba, Israel. The company was founded in 2011 by Shai Yarkoni. Shai Yarkoni has been the CEO since 2011. Cellect Biotherapeutics was acquired by EnCellX, Inc. from Cellect Biotechnology Ltd. on October 28, 2021.